256 completed. 256 Phase 2, 39 Phase 1, 21 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 256 | Completed 256 |
| Phase 1 | 39 | Completed 39 |
| Phase 3 | 21 | Completed 21 |
Follow Anemia, Hemolytic: new trials by email Literature Review of Anemia, Hemolytic trials Research Report on Anemia, Hemolytic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Omega 3 Fatty Acids on Heart and Liver in Beta Thalassemia Patients Omega 3 Fish Oil supplements, Deferasirox - Thalassemia Majors (Beta-Thalassemia Major) | Phase 2 | Completed | Ain Shams University | 100 | 2026-01-01 | 2026-10-07 |
| A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD) HBI-002 - Anemia, Sickle Cell | Phase 2 | Completed | Hillhurst Biopharmaceuticals, Inc. | 13 | 2025-02-15 | 2026-08-06 |
| Zinc for Infection Prevention in Sickle Cell Anemia-2 (ZIPS-2) zinc sulfate, Placebo - Sickle Cell Disease | Phase 2 / Phase 3 | Completed | Indiana University | 100 | 2025-02-10 | 2026-01-30 |
| A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria（PNH） HSK39297 - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Completed | Haisco Pharmaceutical Group Co., Ltd. | 47 | 2024-07-17 | 2025-06-29 |
| Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease Etavopivat - Sickle Cell Disease | Phase 2 | Completed | Novo Nordisk A/S | 12 | 2024-03-09 | 2026-04-08 |
| Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease Epeleuton - Sickle Cell Disease | Phase 2 | Completed | Afimmune | 35 | 2024-01-10 | 2026-05-04 |
| Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria HRS-5965 tablets - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Completed | Chengdu Suncadia Medicine Co., Ltd. | 26 | 2023-11-15 | 2024-10-15 |
| Assessing Physical Function in Sickle Cell Patients Taking Voxelotor Voxelotor - Sickle Cell Disease | Phase 2 | Completed | Inova Health Care Services | 6 | 2023-10-23 | 2026-08-31 |
| Effect of L-Glutamine on Pulmonary Artery Pressure in Patients With Non-Transfusion-Dependent Thalassemia L-glutamine - Pulmonary Artery Pressure, Thalassemia | Phase 2 / Phase 3 | Completed | Mazandaran University of Medical Sciences | 8 | 2023-08-15 | 2025-10-07 |
| A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) MY008211A tablets - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Completed | Wuhan Createrna Science and Technology Co., Ltd | 34 | 2023-07-06 | 2025-07-30 |
| An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4) Povetacicept - Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia | Phase 1 / Phase 2 | Completed | Alpine Immune Sciences Inc, A Subsidiary of Vertex | 30 | 2023-07-03 | 2026-09-14 |
| Hydroxyurea and EPO in Sickle Cell Disease Hydroxyurea, Epoetin Alfa-BioSimilar - Anemia, Sickle Cell, Sickle Cell Disease | Phase 1 / Phase 2 | Completed | Julia Xu | 17 | 2023-05-25 | 2026-01-07 |
| Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab OMS906 - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Completed | Omeros Corporation | 12 | 2023-03-27 | 2025-10-01 |
| A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS INM004, SoC - Diarrhea-Associated Hemolytic Uremic Syndrome, Pediatric Kidney Disease | Phase 2 | Completed | Inmunova S.A. | 57 | 2022-10-06 | 2023-08-21 |
| Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease. Hydroxycarbamide - Sickle Cell Disease | Phase 2 | Completed | Theravia | 33 | 2022-07-08 | 2022-11-23 |
| Research Study Investigating How Well NDec Works in People With Sickle Cell Disease NDec - oral decitabine-tetrahydrouridine, HU - Hydroxyurea, Placebo - Sickle Cell Disease | Phase 2 | Completed | Novo Nordisk A/S | 96 | 2022-07-07 | 2026-07-22 |
| Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded Patients CN128 Tablets - Thalassemia, Iron Overload | Phase 2 | Completed | Hangzhou Zede Pharma-Tech Co., Ltd. | 16 | 2022-06-13 | 2025-03-14 |
| Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) Treosulfan, Fludarabine Phosphate, Tacrolimus - Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 40 | 2022-04-19 | 2026-03-09 |
| A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease Etavopivat tablets - Sickle Cell Disease, Thalassemia | Phase 2 | Completed | Forma Therapeutics, Inc. | 53 | 2022-03-28 | 2025-12-16 |
| Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease Low Dose Rifaximin ER, Low Dose Rifaximin DER, High Dose Rifaximin ER - Sickle Cell Disease | Phase 2 | Completed | Bausch Health Americas, Inc. | 44 | 2022-03-22 | 2024-09-19 |
Showing 20 of 256. Sign in to see all of them.
Anemia, Sickle Cell (140) · beta-Thalassemia (42) · Thalassemia (39) · Hemoglobinuria, Paroxysmal (38) · Anemia (19) · Hematologic Diseases (18) · Iron Overload (16) · Hemoglobinopathies (13) · Vaso-Occlusive Crises (13) · Anemia, Hemolytic, Autoimmune (11) · Genetic Diseases, Inborn (11) · Anemia, Aplastic (10) · Anemia, Diamond-Blackfan (10) · Myelodysplastic Syndromes (10) · Atypical Hemolytic Uremic Syndrome (9)
Hemic and Lymphatic Diseases (256) · Hematologic Diseases (238) · Anemia (237) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (200) · Anemia, Hemolytic, Congenital (195) · Genetic Diseases, Inborn (189) · Hemoglobinopathies (178) · Bone Marrow Diseases (51) · Pathological Conditions, Signs and Symptoms (50) · Pathologic Processes (36) · Nutritional and Metabolic Diseases (34) · Myelodysplastic Syndromes (32) · Metabolic Diseases (30) · Thalassemia (30)
Hydroxyurea (23) · Deferasirox (17) · eculizumab (12) · Busulfan (11) · fludarabine phosphate (11) · Alemtuzumab (10) · Cyclophosphamide (10) · fludarabine (10) · Antilymphocyte Serum (9) · Bone Marrow Transplantation (9) · Deferoxamine (8) · Melphalan (8) · Whole-Body Irradiation (8) · Mycophenolic Acid (7) · thymoglobulin (6)
Novartis Pharmaceuticals (20) · Alexion Pharmaceuticals, Inc. (14) · National Heart, Lung, and Blood Institute (NHLBI) (9) · UCSF Benioff Children's Hospital Oakland (8) · Assistance Publique - Hôpitaux de Paris (6) · St. Jude Children's Research Hospital (6) · Children's Hospital Medical Center, Cincinnati (4) · Fred Hutchinson Cancer Center (4) · Johns Hopkins University (4) · Medical College of Wisconsin (4) · Boston University (3) · Carelon Research (3) · Emory University (3) · HemaQuest Pharmaceuticals Inc. (3) · Hoffmann-La Roche (3)
United States (159) · United Kingdom (41) · Italy (37) · France (30) · Canada (25) · Lebanon (21) · Germany (18) · Thailand (13) · Turkey (Türkiye) (13) · Greece (12) · Netherlands (10) · Egypt (9) · South Korea (9) · Spain (9) · China (7)
Claudia Morris, MD (3) · Mark Walters (3) · Ahmed F Mahmoud Hussein, MS.c (2) · Andrew M Yeager, MD (2) · Dr. Anita Hill (2) · Geir E Tjonnfjord, MD, PhD (2) · Gregory Hale, M.D. (2) · Helen Thackray, MD (2) · Hemant Misra, PhD (2) · Kenneth I Ataga, MBBS (2) · Lakshmanan Krishnamurti, MD (2)
PMID 33783815, PMID 23738544, PMID 34175041, PMID 36240296, PMID 37975597, PMID 33283989, PMID 34922648, PMID 36355805, PMID 36529836, PMID 38775255, PMID 40569673, PMID 17233848, PMID 18192510, PMID 18550258, PMID 19208097, PMID 20421452, PMID 20634373, PMID 20841509, PMID 20955402, PMID 21173101, PMID 21222185, PMID 21364138, PMID 21393329, PMID 21477202, PMID 21700776, PMID 21742281, PMID 21877169, PMID 22129980, PMID 22251482, PMID 22571408, PMID 2265118, PMID 22887019, PMID 22924607, PMID 23151373, PMID 23410147, PMID 23416852, PMID 23553596, PMID 23585527, PMID 23645695, PMID 23828223, PMID 23934275, PMID 24370862, PMID 24385534, PMID 24443249, PMID 24445353, PMID 24452753, PMID 24976388, PMID 24988449, PMID 25212456, PMID 25345697
2016 (6), 2017 (6), 2014 (5), 2015 (3), 2018 (3), U01HL065238 (3), 2023 (2), P30CA015704 (2), U10HL069294 (2), U24CA076518 (2), 1UG3AT011265-01 (1), 2004 (1), 2009 (1), 2019 (1), 3UL1RR025005 (1)